2. Protein Tyrosine Kinase/RTK
  3. c-Fms
  4. Cabiralizumab

Cabiralizumab  (Synonyms: FPA 008; Anti-Human CSF1R Recombinant Antibody)

Cat. No.: HY-P99259 Purity: 99.59%
SDS
COA
Technical Support

Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research.

For research use only. We do not sell to patients.

CAS No. : 1613144-80-1

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Cabiralizumab Featured Recommendations:

Cabiralizumab Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research[1][2][3][4].

Isotype

Human IgG4 kappa
Recommend Isotype Controls
Species

Humanized
IC50 & Target

CSF1R[1]
In Vitro

Cabiralizumab (7 days) disrupts circulating tumor cells (CTC) cluster formation and increases CTC apoptosis in pancreatic ductal adenocarcinoma (PDAC) patient portal blood mononuclear cells (PortalBMC) unsorted samples[4].
Cabiralizumab (7 days) can re-activate PDAC patient T cells (CD3+CD25+CTLA4-PD1L1-) and increases IFNγproduction in PortalBMC[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cabiralizumab Related Antibodies
In Vivo

Cabiralizumab (200-400 μg; i.p.; twice a week for 5 times) (anti-CSF1R) has anti-tumor activity and are inferior at higher doses to lower doses in mice model 3.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57Bl6 male mice model (YUMMER1.7 (UV irradiated derivative of YUMM1.7 carrying a higher number of somatic mutations) or YUMM1.7 (BrafV600E /Pten−/−, Cdkn2a−/−) cells were subcutaneously injected into the left flank) (8-9 week old)[3]
Dosage: 200, 400 μg
Administration: Intraperitoneal injection (i.p.); twice a week for 5 times
Result: In the group treated with higher dose αCSF1R, 55% of mice (11/20) reached endpoint, whereas mice treated with lower dose αCSF1R fared better with 25% (5/20) reaching the endpoint in YUMMER1.7 mice model.
Lower αCSF1R dose resulted in improved survival compared to the higher αCSF1R dose in YUMMER1.7 mice model.
Treatment with both lower and higher anti-CSF1R dose delayed the tumor growth, but all tumors eventually grew out to endpoint in YUMM1.7 mice model.
Clinical Trial
Molecular Weight

146300.00

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Cabiralizumab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG4 kappa
Biological Activity
  • Immobilized Human M-CSFR/CSF1R Protein can bind Cabiralizumab. The EC50 for this effect is 2.465 ng/mL.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Cabiralizumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Cabiralizumab1613144-80-1FPA 008 Anti-Human CSF1R Recombinant AntibodyFPA008FPA-008c-FmsCSF-1 receptorcolony stimulating factor 1 receptorCSF-1RCSF1RT cellarthritisRAlung cancerimmune responsetumorInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Cabiralizumab
Cat. No.:
HY-P99259
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.